Progress in Geographic Atrophy Treatment Approvals in Australia
Date: 5/08/2026 (AEST)
Venue: https://www.carinaleaguesclub.com.au/functions/, QLD, 4152
Provider: LVF Ophthalmology Research Centre
Contact: Michelle Carley-Lep, [E] admin@lvfeyecentre.org.au, [P] 07 3398 9494
Activity Outline
Geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration, has shifted from an untreatable diagnosis to one with two TGA-approved complement-inhibitor therapies: pegcetacoplan (Syfovre), registered in January 2025, and avacincaptad pegol (Izervay), registered in October 2025. This session moves beyond the headlines to give optometrists a practical, evidence-based framework for the new era of dry AMD co-management.
We begin with the Australian access reality - TGA registration, current PBS/PBAC status, and what this means for patient counselling and out-of-pocket considerations. From there, the focus turns to where optometrists add the greatest value: detecting GA earlier and referring at the right moment.
The core of the session is an OCT biomarker masterclass - moving beyond fundus autofluorescence pattern recognition to the structural signs that precede irreversible atrophy: incomplete and complete RPE and outer retinal atrophy (iRORA/cRORA), choroidal hypertransmission, outer retinal subsidence, intraretinal hyperreflective foci, and ellipsoid zone loss. We examine why the subfoveal versus non-subfoveal distinction inverts clinical intuition, and why a patient with 6/6 vision may be the most urgent referral.
We address the field honestly: the structural–functional paradox (slowed lesion growth without proven visual acuity benefit), the macular neovascularisation conversion risk, and a balanced appraisal of both approved agents. Interactive OCT-based cases let participants test their own "refer, monitor, or reassure" reasoning. Finally, we preview the pipeline - gene therapy and oral complement inhibition - that may redefine treatment burden within this decade.
Participants will leave with a clear referral framework and the diagnostic confidence to identify treatable GA before central vision is lost.
Learning Objectives
- Describe the current TGA approval and PBS reimbursement status of pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) for geographic atrophy in Australia.
- Identify key OCT biomarkers of early and progressive geographic atrophy — including iRORA, cRORA, choroidal hypertransmission, hyperreflective foci, and ellipsoid zone loss — using standard practice imaging.
- Differentiate subfoveal from non-subfoveal GA lesions and explain how lesion location, focality, and growth rate influence treatment candidacy and referral urgency.
- Critically appraise the efficacy and safety evidence for complement-inhibitor therapy, including the structural–functional paradox and the risk of conversion to neovascular AMD.
- Apply an evidence-based referral framework to determine which GA patients to refer, monitor, or reassure in a co-management setting.
Max CPD hours awarded: 2.5
Session Information
| Name |
|---|
| Progress in Geographic Atrophy Treatment Approvals in Australia |
| Clinical? |
| Yes |
| Interactive? |
| Yes |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 2.5 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 2.5 |